New disease perspectives and goals of therapy in CLL
|
|
- Arthur Page
- 8 years ago
- Views:
Transcription
1 New disease perspectives and goals of therapy in CLL
2 Contents Introduction 3 CLL overview 4 Patient population 4 Predisposing factors 4 Biology and pathophysiology 5 Clinical presentation 7 Clinical diagnosis and staging 7 Treatment initiation 9 Prognostic markers 10 Chromosomal aberrations 11 IgV H gene mutation status 12 Zeta-chain associated protein kinase 70 (ZAP-70) 13 CD38 expression 13 Prognostic markers in current practice 13 Evolving treatment expectations 15 Evaluating outcomes 16 Minimal residual disease (MRD) 16 Considering the patient 18 Managing older patients 18 Conclusions 19 2
3 Introduction The understanding and management of patients with chronic lymphocytic leukemia (CLL) have evolved significantly over the past several decades. Clinical management strategies for CLL have expanded beyond palliation to improvements in long-term outcomes. Prior to 1980, the opportunity to impact the course of the disease was limited because of the narrow spectrum of therapeutic options and the inability to adequately assess genetic, molecular, and prognostic features. 1 Advances in the knowledge of CLL biology, new treatment and supportive care strategies, and improved diagnostic and prognostic analyses have led to new treatment goals and a change in outlook for patients with the disease. 2 The following sections review patient characteristics, the pathophysiology of CLL, guidelines for diagnosis and staging, treatment options, and important goals of therapy. Additional topics of discussion include new molecular markers that are being evaluated as potential prognostic indicators. This monograph will also explore recent advances in the understanding of CLL biology and how this progress has led to an evolution in treatment goals and management of the disease. 3
4 CLL overview CLL is the most common leukemia in adults in Western countries and represents approximately 25% to 30% of all adult leukemias. 3,4 In the United States, an estimated 15,000 new patients were diagnosed with CLL in 2008, while the prevalence was approximately 95,000 that same year. 5 Patient population CLL is considered to be mainly a disease of the elderly, accounting for 40% of all leukemias in patients over the age of The median age of diagnosis in the United States is 72 years. Approximately 8.9% of cases are diagnosed between ages 45 and 54, and incidence rapidly increases at age Because the CLL patient population is often elderly, the majority of patients typically have a number of comorbidities, such as diabetes and heart disease, that may limit treatment options. 7,8 Patients with CLL vary in ethnicity, age, and gender. Geographic and ethnic differences are particularly important. In Asian countries, CLL represents only 5% of all leukemias. 3 In the United States, the incidence is highest in Caucasian individuals, followed by African Americans and Hispanics. Asian or Pacific Islander Americans and Native Americans (including Alaskans) have the lowest incidence of the disease. 5,9,10 Men are approximately twice as likely to be diagnosed with CLL as women, and most men present with later-stage disease. Conversely, women with CLL are more likely to present with early-stage disease and have a better prognosis than men, regardless of stage and age. 11,12 Predisposing factors Unlike other leukemias, there is no firm evidence linking environmental or occupational exposure with the incidence of CLL except for exposure to Agent Orange. 11,13,14 However, recent research has demonstrated an increased risk in first-degree relatives of patients with CLL. Therefore, a family history of CLL or other lymphoproliferative disorder may also be a CLL risk factor. 3,15 4
5 Biology and pathophysiology CLL is characterized as an abnormal proliferation of malignant B lymphocytes. 9 CLL was once thought to be a homogeneous disease, in which mature B cells accumulated largely due to a lack of normal cell death. Recently, however, CLL has been established as a heterogeneous disease of remarkable diversity. Differences in cell morphology, immunophenotype, cytogenetics, and molecular characteristics have been identified. This heterogeneity translates into varying clinical courses and responses to treatment. 16 Figure 1 provides a historical overview of some of the changes in how CLL biology is viewed. Lymphocytosis is a hallmark of CLL. 11 Malignant lymphocytes characteristically appear small and mature, although large atypical cells, cleaved cells, or prolymphocytic cells are also observed. 3,17 In CLL, malignant, long-lived lymphocytes accumulate in the blood, bone marrow, spleen, and lymph nodes. 4,11 The phenotype of CLL distinguishes it from other B-cell malignancies by the presence of B-cell markers (CD19, CD20, CD23, and CD43) along with CD5, an antigen normally found on T cells. Typically, CLL cells also express surface immunoglobulin (slg), CD79b, CD20, and CD22 at low density. 4,11 The phenotypic features of CLL are not only used for initial diagnosis, but they also play a role in the assessment of minimal residual disease (MRD), an important prognostic parameter defined as <1 CLL cell in 10,000 leukocytes. 17 CLL is often diagnosed as an indolent disease, with a progressive accumulation of malignant lymphocytes. It has a heterogeneous clinical course, ranging from one that does not require immediate treatment to a rapidly progressive disease that requires aggressive management. 18,19 Patients with advanced stage often present with anemia, neutropenia, and thrombocytopenia. 3 In approximately 2% to 6% of patients, the disease undergoes a transformation to large cell lymphoma, which is referred to as Richter s transformation. Prognosis after transformation is poor, with a median survival of approximately 6 months. 3 The range of CLL clinical presentations, combined with the often prolonged indolent course, creates unique challenges in diagnosis and staging. Historically, many patients were not diagnosed with CLL until they became symptomatic; today, there is greater early recognition of this disease due to improvements in patient care and routine laboratory analysis of peripheral blood. 1,20 5
6 Figure 1. Comparison of historical and current views of CLL biology 21 Historical view CLL is a clinically heterogeneous disease with a homogeneous cellular origin. CLL is a disease derived from naive B lymphocytes. Leukemic-cell accumulation occurs because of an inherent apoptotic defect involving the entire mass of leukemic cells. CLL is a disease of lymphocyte accumulation. Prognostic markers identify patients at various risk levels (low, intermediate, or high in the Rai staging categories, and A, B, or C in the Binet categories) with an acknowledged heterogeneity in clinical outcomes among patients in the low- and intermediate-risk categories. Current view CLL is a clinically heterogeneous disease originating from B lymphocytes that may differ in activation, maturity, or cellular subgroup. CLL is a disease derived from antigen-experienced B lymphocytes that differ in the level of immunoglobulin variable (v) gene mutations. Investigators believe leukemic cell accumulation occurs because of survival signals from the external environment. CLL is a disease of lymphocyte accumulation with a higher associated level of proliferation than was previously recognized. New molecular biomarkers are used in both diagnosis and prognosis to better assess patients. Adapted from Chiorazzi N et al. N Engl J Med. 2005;352:
7 Clinical presentation CLL is classified based on cell morphology, immunohistochemistry, and flow cytometry. The French- American-British classification system classifies CLL disease in the bone marrow into several groups, referred to as diffuse, nodular, interstitial, or a combination of these groupings, based on the percentage of abnormal cells. 3,11,22 This classification system is further described in Table 1. Table 1. Laboratory findings in CLL impacting classification 11 The French-American-British classification Typical CLL CLL/PLL Atypical CLL >90% of cells are small 11% 54% of cells are prolymphocytes Heterogeneous morphology; <10% prolymphocytes Marrow involvement Diffuse involvement Nodular, interstitial, or combination (nondiffuse involvement) Usually advanced disease; worse prognosis Associated with less advanced disease; better outcomes Clinical diagnosis and staging Today, approximately 40% of patients with CLL are diagnosed in the earlier stages of the disease and are often asymptomatic. Many of these patients have a long symptom-free period. The remaining 60% of patients present with a range of symptoms of which the most common are fatigue, enlarged lymph nodes, and weight loss. However, patients may also present with lymphadenopathy or splenomegaly. Patients with CLL have compromised immune systems and are susceptible to recurrent bacterial and viral infections. 3 Figure 2. IWCLL* update of the NCI-WG criteria for diagnosing CLL 17,23 Update of the NCI-WG criteria for CLL diagnosis A peripheral blood B-lymphocyte count of at least /L, with up to 55% of the cells being prolymphocytes The lymphocytes should be monoclonal B lymphocytes expressing B-cell surface antigens (CD19, CD20, CD23) with light chain restriction and the T-cell antigen CD5 Each clone of leukemia cells is restricted to expression of either kappa or lambda immunoglobulin light chains Variations of the intensity of expression of these markers may exist and do not prevent inclusion of a patient in CLL clinical trials *International Workshop on CLL. The International Workshop on CLL (IWCLL) update of the National Cancer Institute-sponsored Working Group (NCI-WG) has outlined specific criteria for diagnosing CLL, as detailed in Figure 2. A number of other B-cell malignancies cause increased circulating lymphocytes and thus need to be considered in the differential diagnosis. Advances in flow cytometry have allowed immunophenotyping to become a routine diagnostic tool used to differentiate CLL from other diseases, such as mantle cell and marginal zone leukemia/lymphoma, or other leukemias/lymphomas that may resemble CLL. 3,17,24 7
8 Table 2. Rai and Binet staging systems for classification of CLL 18,19,25 System Stage Definition Median survival Rai staging system Binet staging 0 (low risk) I (intermediate risk) II (intermediate risk) III (high risk) IV (high risk) A B C Lymphocytosis only Lymphocytosis and lymphadenopathy Lymphocytosis in blood and marrow with splenomegaly and/or hepatomegaly (with or without lymphadenopathy) Lymphocytosis and anemia (hemoglobin <11 g/dl or hematocrit <33%) Lymphocytosis and thrombocytopenia (platelet count <100,000/mm 3 ) Enlargement of <3 lymphoid areas (cervical, axillary, inguinal, spleen, liver); no anemia or thrombocytopenia Enlargement of 3 lymphoid areas Anemia (hemoglobin <10 g/dl or thrombocytopenia platelet count <100,000/mm 3 ), or both 11.5 years 11.0 years 7.8 years 5.3 years 7.0 years 11.5 years 8.6 years 7.0 years Table 2 summarizes the major staging systems used for the classification of CLL: the original Rai staging system, the modified Rai staging system, and the Binet staging system. 18,19,25 The original Rai system, published in 1975, consists of stages 0 through IV. It is based on the presence of lymphocytosis, lymphadenopathy, organomegaly, and cytopenias. 19 This staging system was later modified from a 5-tier to a 3-tier system that categorizes patients as having a low, intermediate, or high risk for disease progression. 17,25 The Binet system is also a 3-tier system, with categories A through C. It is based on a retrospective analysis of disease burden that correlates lymphocyte count and the degree of bone marrow infiltration with disease progression. 18 Both the Rai and Binet staging systems give a general indication of prognosis. These staging systems are static, do not take patient variability into consideration, and do not predict which patients will progress or require therapy. Moreover, survival within each stage may vary significantly, particularly in patients with Rai stage 0 and Binet stage A. 11 In these groups, a significant percentage of patients have indolent CLL, whereas others have more aggressive disease that may require earlier intervention. 3,16,26 The median survival of patients with Rai stage 0 disease is more than 12 years, and patients with Rai stages I and II have median survival rates of approximately 5 to 10 years. 19 8
9 Treatment initiation Criteria exist to guide oncologists in determining when to initiate treatment in patients with CLL. The updated IWCLL NCI-WG criteria on CLL focus on Rai and/or Binet stage when determining when to treat patients. According to the criteria, newly diagnosed patients with asymptomatic early-stage disease (Rai 0, Binet A) should be monitored without therapy [watch-and-wait approach] unless they have evidence of disease progression.... [P]atients [with] intermediate ([Rai] stages I and II) and high risk [disease] ([Rai] stages III and IV) according to the modified Rai classification or at Binet stage B and C usually benefit from the initiation of treatment.... Thus, treatment according to the NCI-WG criteria depends heavily on disease stage. However, even some later-stage patients, such as those with Rai stage III or IV or Binet stage C disease, can also be followed without therapy until they become symptomatic or their disease progresses. 17 The National Comprehensive Cancer Network (NCCN) provides more detailed guidance for treatment based not only on stage, but also on symptomatology. NCCN guidelines suggest first classifying patients based on the Rai staging system, then further classifying Rai low-risk and Rai intermediate-risk patients according to a list of conditions that influence treatment, including whether the patient has autoimmune cytopenia, recurrent infections, common B symptoms, threatened end-organ function, cytopenias, bulky disease, steady progression, or histologic progression, as described in Figure Figure 3. NCCN CLL indications for treatment 27 NCCN CLL indications Significant disease-related symptoms: Fatigue Night sweats Weight loss Fever without infection Threatened end-organ function Bulky disease (spleen >6 cm beneath costal margin, lymph nodes >10 cm) Lymphocyte doubling time 6 months* Progressive anemia Platelet count <100,000 cells/mm 3 Eligible for clinical trial *Absolute lymphocyte count alone is not an indication for treatment. Given incurability with conventional therapy, consider a clinical trial as first line of treatment. Adapted from National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Non-Hodgkin s Lymphomas. V
10 Prognostic markers The Rai and Binet staging systems are simple and reliable prognostic tools that form the basis of the decision to treat most patients. 11 However, there is considerable variation in outcome with each stage. Therefore, additional factors are more commonly being considered in predicting individual patient prognosis and stratifying patient risks. The World Health Organization (WHO) publications and NCI-WG criteria suggest a number of disease activity markers, such as b 2 -microglobulin, CD23, rapid lymphocyte doubling time, and serum thymidine kinase, for use in predicting patient outcomes. 4,17 In addition, recent advances have identified additional biologic markers, such as IgV H mutational status, chromosomal aberrations, and expression of zeta-chain associated protein kinase 70 (ZAP-70) and CD38, that complement the conventional prognostic factors previously described. 17 These additional biomarkers may be used in conjunction with staging to potentially predict outcome or level of tumor burden, as described in Table Table 3. Markers that identify poor prognosis in CLL 4,11 Routinely available markers Advanced Rai or Binet stage Atypical morphology Peripheral lymphocyte doubling time <12 months Serum markers: elevated thymidine kinase and scd23 Immunophenotyping: dim surface IgM/IgD, CD20+, CD22+, CD5+, CD19+, CD79a+, CD23+, CD43+ High β 2 -microglobulin level Diffuse marrow histology Poor response to chemotherapy Investigational markers Lack of IgV H gene mutation Expression of ZAP-70 protein FISH studies showing trisomy 12q, del 11q, del 17p, del 6q scd23=soluble CD23; FISH=fluorescence in situ hybridization. 10
11 Chromosomal aberrations No single genetic mutation or abnormality responsible for CLL development has been identified. Rather, the disease is characterized by a variety of chromosomal abnormalities. These may be detected in 40% to 50% of patients using chromosome banding and in approximately 80% of patients using fluorescence in situ hybridization (FISH) analysis. 3 The most common genetic aberration identified by FISH in untreated CLL patients is the 13q deletion, which is found in 55% of patients. 28 The next most common aberrations are 11q deletion, trisomy 12q, and 17p deletion, found in 18%, 16%, and 7% of patients, respectively. 28 Genetic aberrations are important predictors of disease outcome; specifically, deletions of 17p and 11q have been associated with poor survival. 28 In a study of 325 patients with CLL, chromosomal deletion at 17p predicted aggressive disease, with patients surviving an average of less than 3 years. Patients with the 11q deletion also had a poor overall prognosis, with a median survival of less than 7 years. Patients with a 13q deletion had a median survival of 11 years and, therefore, more favorable outcomes. 28 The impact of genetic abnormalities on overall survival (OS) of CLL patients is shown in Figure 4. Figure 4. Prognostic implication of chromosomal abnormalities 28 Prognostic implication of chromosomal abnormalities 100 Estimated survival probability p 13q single 40 17p 30 11q q Normal 10 13q single Overall survival (months) Adapted from Döhner H et al. N Engl J Med. 2000;343:
12 IgV H gene mutation status It has been suggested that there are 2 types of CLL, characterized by the presence or absence of a mutated immunoglobulin variable region (IgV H ), which follow distinct clinical courses. These are depicted in Figure 5. CLL patients can be divided into 2 prognostic groups based on mutation status. 29,30 The IgV H mutated group has an approximate survival of 25 years, while the IgV H unmutated group has a more aggressive clinical course and an approximate survival of 10 years. 30 Patients with IgV H gene mutations are also more likely to have a 13q deletion and a good prognosis, whereas those without IgV H gene mutations more frequently have trisomy 12q and a poorer prognosis. 31,32 Although there is an established correlation between IgV H mutation status and prognosis, assays to detect mutation status are not broadly available Thus, other laboratory tests are used as surrogate markers but are still under investigation. 33,34 Figure 5. Schematic of selected biologic differences between IgV H unmutated CLL B-cell clones and IgV H mutated CLL B-cell clones 37 Schematic of selected biological differences between IgV H unmutated and mutated CLL B-cell clones Median survival 8 to 10 years Median survival 25 years High CD38 Low CD38 p53 defects Unmutated lgv H Mutated lgv H Low ZAP-70 High ZAP-70 Poor-risk FISH (ie, 17p ; 11q ) Good-risk FISH (ie, 13q ) Adapted from Shanafelt TD et al. Blood. 2004;103: Blood: journal of the American Society of Hematology Copyright 2004 by AMERICAN SOCIETY OF HEMATOLOGY (ASH). Reproduced with permission of AMERICAN SOCIETY OF HEMATOLOGY (ASH) in the format Internet posting via Copyright Clearance Center. 12
13 Zeta-chain associated protein kinase 70 (ZAP-70) ZAP-70 is a member of the Syk-ZAP-70 protein kinase family. This kinase is normally expressed in T and natural killer (NK) cells, and it plays a role in initiating T-cell signaling and in signaling through the B-cell receptor of CLL cells. 34,38 Recent research exploring ZAP-70 as a potential surrogate marker for IgV H gene mutation status has indicated that ZAP-70 overexpression is correlated with an unmutated IgV H and is predictive of poorer outcomes in CLL. 33,34,38,39 ZAP-70 expression may be measured by flow cytometry, Western blotting, quantitative reverse transcriptase-polymerase chain reaction (qrt-pcr), and immunohistochemistry. 38,39 Currently, assays examining ZAP-70 expression are inconsistent, with no clear guidelines for use. In addition, the correlation between ZAP-70 and outcomes, and its subsequent use as a marker for treatment decisions, remains subject to ongoing debate. 17 In an investigation evaluating ZAP-70 expression as a surrogate for IgV H mutation status, ZAP-70 expression correctly identified 91% of patients with unmutated IgV H genes, and no patient with mutated IgV H genes overexpressed ZAP Overall, there is a strong correlation between ZAP-70 expression and IgV H mutation; however, because ZAP-70 expression has been found to remain unchanged over time, some oncologists believe it to have independent prognostic value. 34,38,40 CD38 expression CD38 expression on CLL cells has been correlated with IgV H mutations. 29 Because CD38 cell-surface expression can be easily detected by flow cytometry, CD38 expression has been suggested as a surrogate marker for determining IgV H mutation status in CLL. 29 However, studies have not supported the role of CD38 as the desired surrogate. This work has indicated that the relationship between CD38 expression and IgV H mutation is not absolute and may be discordant in approximately 30% of cases. 34,41 Furthermore, CD38 expression may also fluctuate in patients, with karyotype evolution occurring in 15% to 40% of patients. 32 CD38 expression and IgV H mutation status are considered independent prognostic indicators. 34,41 In addition, CD38 correlation with outcomes and subsequent use as a marker for treatment remains subject to ongoing debate. 17,35 ZAP-70 and CD38 expression may ultimately provide complementary prognostic information; however, neither CD38 nor ZAP-70 assays are widely used outside of clinical trials. 17,34 Prognostic markers in current practice The recent IWCLL updated the NCI-WG criteria for diagnosis and treatment of patients with CLL to include standard prognostic indicators and possibly a CLL-relevant FISH panel in general practice (Table 4). Although still under debate, the current NCI-WG criteria further recommend that some of the newer molecular biomarkers, such as CD38, IgV H mutation status, and ZAP-70, as mentioned previously, be included in clinical trials
14 Prospective CLL studies that include the newly identified biomarkers will continue to refine the understanding of the clinical behavior and biology of this disease, and will be pivotal in the future refinement of new treatment strategies. Once these assays are perfected and incorporated into clinical practice, they are likely to guide patient management decisions. 35 Chromosomal abnormalities, IgV H mutation status, and ZAP-70 and CD38 expression may ultimately be combined with more established prognostic indicators, such as lymphocyte doubling time, to predict the clinical course of patients. 16 In addition, consideration of response to therapy and the eradication of MRD may be used to help predict patient outcomes. 42 These indicators may guide patient stratification into lowand high-risk populations, optimizing the clinician s ability to individualize treatment strategies to achieve greater clinical goals. 17 Table 4. IWCLL update of the NCI-WG recommendations for pretreatment evaluations of patients with CLL 17 Diagnostic test General practice* Clinical trial Tests to establish diagnosis Complete blood count and differntial count Always Always Immunophenotyping of lymphocytes Always Always Assessment before treatment History and physical, performance status Always Always Complete blood count and differential Always Always Marrow aspirate and biopsy Desirable Desirable Serum chemistry, serum immunoglobulin, direct antiglobulin test Always Always Chest radiograph Always Always Infectious disease status Always Always Additional tests before treatment Cytogenetics (FISH) for del 13q, del 11q, del 17p, trisomy 12q, Desirable Always del 6q in the peripheral blood lymphocytes IgV H mutation status, ZAP-70, and CD38 NGI Always CT scan of chest, abdomen, and pelvis NGI Desirable MRI, lymphangiogram, gallium scan, PET scans NGI NGI Abdominal ultrasound Possible NGI NGI=not generally indicated. * The use of accepted options for a patient with CLL who is not enrolled in a clinical trial. Adapted from Hallek M et al. Blood. 2008;111:
15 Evolving treatment expectations In the past 10 years, the CLL therapeutic landscape has dramatically evolved, as shown in Figure 6. Treatment options expanded from the use of alkylating agent monotherapy in the 1960s and 1970s to the introduction of purine analogs, and moved to combination therapy in the 1980s and 1990s. In the current decade, treatment strategies have expanded to include immunotherapy. 3,43 Figure 6. CLL treatment overview by decade 44 CLL treatment overview by decade Alkylating agents Purine nucleosides Purine nucleosides and alkylators Chemoimmunotherapy Adapted from Kay NE. Blood. 2006;107:848. Blood: journal of the American Society of Hematology Copyright 2004 by AMERICAN SOCIETY OF HEMATOLOGY (ASH). Reproduced with permission of AMERICAN SOCIETY OF HEMATOLOGY (ASH) in the format Internet posting via Copyright Clearance Center. The expansion of the therapeutic landscape has shifted CLL treatment expectations to include both palliative care and symptom management as well as therapy with more response-driven intent. Recent treatment strategies have focused on achieving higher and better quality response rates and longer progression-free survival (PFS) As advances in CLL clinical research have continued to progress into the new millennium, treatment goals have included achieving longer survival as well as improved quality and duration of complete remission, with the hope of achieving MRD negativity. 50 As shown in Figure 7, oncologists have begun to expect CLL therapy to result in improvements in outcomes beyond response rates and into PFS and MRD negativity. As research continues to refine the treatment goals for patients with CLL, the progress in CLL achieved over the past 3 decades is likely to continue. 15
16 Figure 7. CLL treatment expectations by decade 51,52 Goals of treatment for CLL have evolved over time Palliation Palliation, higher response rates CR, FFP CR, PFS PFS, MRD-negative CR FFP=freedom from progression. Evaluating outcomes The NCI-WG recently updated the standard CLL response criteria (shown in Table 5). This update confirms the use of conventional biomarkers, defines new prognostic and predictive markers, and diagnostic parameters, and accommodates new treatment goals and options. 17 Until recently, response to therapy, or overall response rate (ORR), in CLL was determined using the 1996 NCI-WG response criteria defining complete remission, partial response (PR), stable disease (SD), and progressive disease (PD). 17,23 However, most current clinical trials have also included more sensitive evaluation techniques that have since become available. 17 These newer publications include reports on complete molecular remission as well as the standard designations of overall response (OR), complete response (CR), and PR. 17 The incorporation of MRD testing allows oncologists to more closely examine the quality of response to therapy. Improvements in PFS have been observed in patients who achieve CR, and even greater improvements for those achieving MRD negativity. 24,42 This has prompted reevaluation of treatment paradigms to include more vigilant monitoring of the depth of CR through MRD analysis. 42 Minimal residual disease (MRD) Today, MRD negativity is emerging as an important treatment assessment. Despite the growing consensus regarding the importance of MRD negativity and its possible correlation with long-term treatment outcomes, MRD assessment is not widely used. 3 MRD negativity is the eradication of disease to undetectable levels, defined as <1 CLL cell in 10,000 leukocytes. 17 Because MRD assessment leads to a more accurate prognosis, it has been added to the NCI-WG criteria for clinical trials as a goal of therapy. 17 Patients who achieve MRD negativity after therapy usually have a better prognosis than those with lowerquality responses to therapy. 53,54 In clinical studies, it has been reported that CLL patients achieving MRD-negative status generally had longer disease-free periods and better OS than MRD-positive patients. These findings stress the importance of eradicating disease at the molecular level. 53,54 MRD negativity may, therefore, become a decisive indicator of treatment success
17 Table revision of the NCI-WG criteria for response in CLL 17 Treatment goals in CLL Complete response (CR) Partial response (PR) Stable disease (SD) Progressive disease (PD) Progressive-free survival (PFS) Treatment failure Relapse Refractory Minimal residual disease (MRD) Definition At 2 months posttherapy: Absence of lymphadenopathy >1.5 cm, hepatomegaly, splenomegaly, and constitutional symptoms Normalization of CBC (neutrophils >1,500/µL, platelets >100,000/µL, hemoglobin >11 g/dl) Lymphocytes <4,000/µL Additional assessments in clinical trials: - Minimal residual disease (MRD) <1 CLL cell per 10,000 leukocytes - Bone marrow biopsy shows normal cellularity, lymphocytes <30% At 2 months posttherapy: A decrease in the number of blood lymphocytes by 50% from the value before therapy Reduction in lymphadenopathy (by CT scans in clinical trials or by palpation in clinical practice) as defined by - Decrease in lymph node size by 50% - No increase in any lymph node, and no new enlarged node(s) detected Normalization of CBC (neutrophils >1,500/µL or 50% improvement over baseline; platelets >100,00/µL or 50% improvement over baseline; hemoglobin >11 g/dl or 50% over baseline) No CR or PR, no progressive disease At least 1 of the following: Lymphadenopathy ( 50% increase) 50% increase in hepatomegaly or splenomegaly Transformation to a more aggresive histology (Richter s transformation) Occurrence of cytopenia (neutropenia, anemia, or thrombocytopenia) attributable to CLL The time from study entry until objective disease progression or death Includes the following responses: Stable disease Nonresponse Progressive disease Death from any cause Patient achieved CR or PR but at 6 months shows evidence of disease progression Treatment failure or disease progression within 6 months of the last antileukemic therapy For patients who have achieved a CR, eradication of disease cells as determined by flow cytometry or PCR (<1 CLL cell per 10,000 leukocytes) Adapted from Hallek M et al. Blood. 2008;111:
18 Considering the patient Fine-tuning treatment and goals of therapy based on the unique characteristics of each patient is an important consideration in CLL management. Medical fitness, age, and the ability to tolerate aggressive therapy are critical and interrelated patient characteristics that should all be considered when choosing a treatment regimen. Medical fitness is receiving greater attention in CLL treatment planning. Medically fit patients have normal organ function, no additional health problems or only mild, nondebilitating health problems, and a good performance status. Conversely, medically unfit patients may present with a worse performance status or reduced organ function, as well as multiple or severe comorbidities that should be considered in treatment decisions. 55 Age is another critical factor when individualizing treatment goals. However, the effects of aging differ greatly among individuals, and treatment plans should account for this diversity. Younger patients typically have good medical fitness with few comorbidities. Conversely, the majority of CLL patients present at an older age and may have significant comorbidities. However, age does not automatically dictate medical unfitness. Therefore, regardless of a patient s age, the patient s medical history should be considered. Thus, a treatment algorithm should not be devised based exclusively on patient age. 3,8 Managing older patients The management of older patients with CLL involves identifying those who may tolerate and benefit from more aggressive therapy. 8 Data are emerging that confirm many patients over 65 are able to tolerate and benefit from more aggressive therapy. 56 However, many oncologists believe that the toxicity of some therapies is not well tolerated by patients 70 years or older. 2 While age has been defined as an important factor in selecting optimal treatment strategies, it should also be recognized that there is significant heterogeneity in the elderly population with regards to medical fitness and the risk of disease progression. Thus, a one-size-fits-all approach to the treatment of this patient population may not be ideal. Devising treatment strategies for elderly patients is also made difficult by the fact that this population is often underrepresented in clinical trials. In a recent review of available scientific literature pertaining to elderly CLL patients, Eichhorst et al concluded that medically fit patients with no or mild comorbidity and normal life expectancy should be treated intensively irrespective of their chronological age. 2 18
19 Conclusions Over the past 3 decades, an increased understanding of the biology of CLL, advances in diagnostic and prognostic analyses, new treatment strategies, and better supportive care have all led to improved patient outcomes. 1 The conventional view of CLL as a disease treated with palliation has now evolved to focus on improving long-term patient outcomes. 1,57 CLL treatments have expanded from alkylating agents, to combining purine analogs with alkylators, to the addition of immunotherapy. This increase in treatment options has resulted in a concomitant increase in complete response rates compared with prior generations of therapy. 1 Today, the goals of treatment for patients with CLL include high-quality responses, including CR with MRD negativity, duration of response, and PFS. 17 Oncologists have begun to refine and tailor treatment strategies for a more individualized approach that is based on patient characteristics. Ongoing scientific research in this field will continue to contribute to improved outcomes in CLL over the coming decades. 19
20 References: 1. Brenner H, Gondos A, Pulte D. Trends in long-term survival of patients with chronic lymphocytic leukemia from the 1980s to the early 21st century. Blood. 2008;111: Eichhorst B, Goede V, Hallek M. Treatment of elderly patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2009;50: Wierda WG, Keating MJ, O Brien S. Chronic lymphocytic leukemias. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer Principles & Practice of Oncology. 8th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2008: Müller-Hermelink HK, Montserrat E, Catovsky D, et al. Chronic lymphocytic leukaemia/small lymphocytic lymphoma. In: Swerdlow SH, Campo E, Harris NL, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: International Agency for Research on Cancer; 2008: Horner MJ, Ries LAG, Krapcho M, et al. SEER Cancer Statistics Review, Accessed May 15, British Society for Haematology. Guidelines on the diagnosis and management of chronic lymphocytic leukaemia. Br J Haematol. 2004;125: Thurmes P, Call T, Slager S, et al. Comorbid conditions and survival in unselected, newly diagnosed patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2008;49: Extermann M, Overcash J, Lyman GH, et al. Comorbidity and functional status are independent in older cancer patients. J Clin Oncol. 1998;16: Watson L, Wyld P, Catovsky D. Disease burden of chronic lymphocytic leukaemia within the European Union. Eur J Haematol. 2008;81: Zent CS, Kyasa MJ, Evans R, et al. Chronic lymphocytic leukemia incidence is substantially higher than estimated from tumor registry data. Cancer. 2001;92: Johnston JB, Seftel M, Gibson SB. Chronic lymphocytic leukemia. In: Greer JP, Foerster J, Rodgers GM, et al, eds. Wintrobe s Clinical Hematology. 12th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2009: Catovsky D, Fooks J, Richards S; for MRC Working Party on Leukaemia in Adults. Prognostic factors in chronic lymphocytic leukaemia: the importance of age, sex and response to treatment in survival. Br J Haematol. 1989;72: Dawson G. Chronic lymphocytic leukemia associated with Agent Orange. J Natl Med Assoc. 2003;95:A Chamie K, DeVere White RW, Lee D, et al. Agent Orange exposure, Vietnam War veterans, and the risk of prostate cancer. Cancer. 2008;113: Rawstron AC, Yuille MR, Fuller J, et al. Inherited predisposition to CLL is detectable as subclinical monoclonal B-lymphocyte expansion. Blood. 2002;100: Wierda WG, O Brien S, Wang X, et al. Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. Blood. 2007;109: Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111: Binet JL, Auquier A, Dighiero G, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer. 1981;48: Rai KR, Sawitsky A, Cronkite EP, et al. Clinical staging of chronic lymphocytic leukemia. Blood. 1975;46: CLL Trialists Collaborative Group. Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials. J Natl Cancer Inst. 1999;91: Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med. 2005;352: Bennett JM, Catovsky D, Daniel MT, et al; for French-American-British (FAB) Cooperative Group. Proposals for the classification of chronic (mature) B and T lymphoid leukaemias. J Clin Pathol. 1989;42: Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 1996;87: Rawstron AC, Villamor N, Ritgen M, et al. International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia. Leukemia. 2007;21: Rai KR. A critical analysis of staging in CLL. In: Gale PR, Rai KR, eds. Chronic Lymphocytic Leukemia: Recent Progress and Future Direction. New York, NY: Alan R. Liss, Inc.; 1987: French Cooperative Group on Chronic Lymphocytic Leukaemia. Natural history of stage A chronic lymphocytic leukaemia untreated patients. Br J Haematol. 1990;76: National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Non-Hodgkin s Lymphomas. nhl.pdf. V Accessed May 1, Döhner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343: Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 1999;94: Hamblin TJ, Davis Z, Gardiner A, et al. Unmutated Ig VH genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999;94: Kröber A, Seiler T, Benner A, et al. VH mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood. 2002;100: Oscier DG, Gardiner AC, Mould SJ, et al. Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. Blood. 2002;100: Orchard JA, Ibbotson RE, Davis Z, et al. ZAP-70 expression and prognosis in chronic lymphocytic leukaemia. Lancet. 2004;363: Del Principe MI, Del Poeta G, Buccisano F, et al. Clinical significance of ZAP-70 protein expression in B-cell chronic lymphocytic leukemia. Blood. 2006;108: Hus I, Podhorecka M, Bojarska-Junak A, et al. The clinical significance of ZAP-70 and CD38 expression in B-cell chronic lymphocytic leukaemia. Ann Oncol. 2006;17: Shanafelt TD, Jenkins G, Call TG, et al. Validation of a new prognostic index for patients with chronic lymphocytic leukemia. Cancer. 2009;115: Shanafelt TD, Geyer SM, Kay NE. Prognosis at diagnosis: integrating molecular biologic insights into clinical practice for patients with CLL. Blood. 2004;103: Crespo M, Bosch F, Villamor N, et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med. 2003;348: Wiestner A, Rosenwald A, Barry TS, et al. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood. 2003;101: Rassenti LZ, Huynh L, Toy TL, et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med. 2004;351: Hamblin TJ, Orchard JA, Ibbotson RE, et al. CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. Blood. 2002;99: Rawstron AC, Kennedy B, Evans PAS, et al. Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy. Blood. 2001;98: US Food and Drug Administration Web site. Drugs at FDA: FDA approved drug products. DrugsatFDA/index.cfm?fuseaction=Search.SearchResults_Browse&StartRow=201&StepSize=100. Accessed March 13, Kay NE. Treatment and evaluation of CLL: a complicated affair. Blood. 2006;107: International Workshop on Chronic Lymphocytic Leukemia. Chronic lymphocytic leukemia: recommendations for diagnosis, staging, and response criteria. Ann Intern Med. 1989;110: Montserrat E, Alcalá A, Parody R, et al. A randomized trial comparing chlorambucil plus prednisone versus cyclophosphamide, vincristine, and prednisone. Cancer. 1985;56: Leporrier M, Chevret S, Cazin B, et al. Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. Blood. 2001;98: Keating MJ, O Brien S, Kantarjian H, et al. Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent. Blood. 1993;81: Rai KR, Peterson BL, Appelbaum FR, et al. 20
21 Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med. 2000;343: Hillmen P, Skotnicki AB, Robak T, et al. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol. 2007;25: Montserrat E. Treatment of chronic lymphocytic leukemia: achieving minimal residual disease negative status as a goal. J Clin Oncol. 2005;23: Montserrat E. CLL therapy: progress at last! Blood. 2005;105: Moreton P, Kennedy B, Lucas G, et al. Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol. 2005;23: Bosch F, Ferrer A, López-Guillermo A, et al. Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia. Br J Haematol. 2002;119: Goede V, Hallek M. State-of-the-art treatment of chronic lymphocytic leukaemia. EJHP Pract. 2008;14: Fabbri A, Lenoci M, Gozzetti A, et al. Low-dose oral fludarabine plus cyclophosphamide in elderly patients with chronic lymphoproliferative disorders. Hematol J. 2004;5: Mentzer SJ, Osteen RT, Starnes HF, et al. Splenic enlargement and hyperfunction as indications for splenectomy in chronic leukemia. Ann Surg. 1987;205: Genentech USA, Inc. All rights reserved. GA Printed in USA.
Supplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Farooqui MZH, Valdez J, Martyr S, et al. Ibrutinib
More informationAn overview of CLL care and treatment. Dr Dean Smith Haematology Consultant City Hospital Nottingham
An overview of CLL care and treatment Dr Dean Smith Haematology Consultant City Hospital Nottingham What is CLL? CLL (Chronic Lymphocytic Leukaemia) is a type of cancer in which the bone marrow makes too
More informationWhy discuss CLL? Common: 40% of US leukaemia. approx 100 pa in SJH / MWHB 3 inpatients in SJH at any time
Why discuss CLL? Common: 40% of US leukaemia approx 100 pa in SJH / MWHB 3 inpatients in SJH at any time Median age of dx is 65 (30s. Incurable, survival 2-202 20 years Require ongoing supportive care
More informationChronic Lymphocytic Leukemia. Case Study. AAIM Triennial October 2012 Susan Sokoloski, M.D.
Chronic Lymphocytic Leukemia AAIM Triennial October 2012 Susan Sokoloski, M.D. Case Study 57 year old male, trial application for $1,000,000 Universal Life coverage Cover letter from sales agent indicates
More informationCHRONIC LYMPHOCYTIC LEUKEMIA
CHRONIC LYMPHOCYTIC LEUKEMIA Executive Summary Chronic lymphocytic leukemia (CLL) is the most common form of leukemia in the Western world, but is significantly less frequent in Asia. The median age of
More informationC H R O N I C L Y M P H O C Y T I C L E U K E M I A
Review of Current Treatment Options and Evidence for the Use of Rituximab (Rituxan ) in the Treatment of C H R O N I C L Y M P H O C Y T I C L E U K E M I A Rituximab (Rituxan ) in the Treatment of Chronic
More informationChronic lymphocytic EBMT Slideleukemia. University of Heidelberg, Germany March 22, 2010. The European Group for Blood and Marrow Transplantation
Chronic lymphocytic EBMT Slideleukemia template Peter Barcelona Dreger Chairman, CLL 7 February subcommittee 2008 University of Heidelberg, Germany March 22, 2010 The European Group for Blood and Marrow
More informationCLL: Disease Course, Treatment, Diagnosis, and Biomarkers
CLL: Disease Course, Treatment, Diagnosis, and Biomarkers Amy E. Hanlon Newell, Ph.D. Manager, Scientific Affairs Abbott Molecular Overview: Today s Take-away Understanding of: Cell phenotype and clinical
More informationMalignant Lymphomas and Plasma Cell Myeloma
Malignant Lymphomas and Plasma Cell Myeloma Dr. Bruce F. Burns Dept. of Pathology and Lab Medicine Overview definitions - lymphoma lymphoproliferative disorder plasma cell myeloma pathogenesis - translocations
More informationInteresting Case Review. Renuka Agrawal, MD Dept. of Pathology City of Hope National Medical Center Duarte, CA
Interesting Case Review Renuka Agrawal, MD Dept. of Pathology City of Hope National Medical Center Duarte, CA History 63 y/o male with h/o CLL for 10 years Presents with worsening renal function and hypercalcemia
More information亞 東 紀 念 醫 院 Follicular Lymphoma 臨 床 指 引
前 言 : 惡 性 淋 巴 瘤 ( 或 簡 稱 淋 巴 癌 ) 乃 由 體 內 淋 巴 系 統 包 括 淋 巴 細 胞 淋 巴 管 淋 巴 腺 及 一 些 淋 巴 器 官 或 組 織 如 脾 臟 胸 腺 及 扁 桃 腺 等 所 長 出 的 惡 性 腫 瘤 依 腫 瘤 病 理 組 織 型 態 的 不 同 可 分 為 何 杰 金 氏 淋 巴 瘤 (Hodgkin s disease) 與 非 何 杰 金
More informationCorporate Medical Policy
Corporate Medical Policy Hematopoietic Stem-Cell Transplantation for CLL and SLL File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem-cell_transplantation_for_cll_and_sll
More informationAggressive lymphomas. Michael Crump Princess Margaret Hospital
Aggressive lymphomas Michael Crump Princess Margaret Hospital What are the aggressive lymphomas? Diffuse large B cell Mediastinal large B cell Anaplastic large cell Burkitt lymphoma (transformed lymphoma:
More informationLYMPHOMA. BACHIR ALOBEID, M.D. HEMATOPATHOLOGY DIVISION PATHOLOGY DEPARTMENT Columbia University/ College of Physicians & Surgeons
LYMPHOMA BACHIR ALOBEID, M.D. HEMATOPATHOLOGY DIVISION PATHOLOGY DEPARTMENT Columbia University/ College of Physicians & Surgeons Normal development of lymphocytes Lymphocyte proliferation and differentiation:
More informationUNDERSTANDING MULTIPLE MYELOMA AND LABORATORY VALUES Benjamin Parsons, DO bmparson@gundersenhealth.org Gundersen Health System Center for Cancer and
UNDERSTANDING MULTIPLE MYELOMA AND LABORATORY VALUES Benjamin Parsons, DO bmparson@gundersenhealth.org Gundersen Health System Center for Cancer and Blood Disorders La Crosse, WI UNDERSTANDING MULTIPLE
More informationWaldenström Macroglobulinemia: The Burning Questions. IWMF Ed Forum May 18 2014 Morie Gertz MD, MACP
Waldenström Macroglobulinemia: The Burning Questions IWMF Ed Forum May 18 2014 Morie Gertz MD, MACP Are my kids going to get this? Familial seen in approximately 5 10% of all CLL patients and can be associated
More informationWhat is chronic lymphocytic leukaemia?
Revised October 2011 What is chronic lymphocytic leukaemia? The diagnosis of a blood cancer can be a devastating event for patients, families and friends. It is therefore vital for everyone to have access
More informationMALIGNANT LYMPHOMAS. Dr. Olga Vujovic (Updated August 2010)
MALIGNANT LYMPHOMAS Dr. Olga Vujovic (Updated August 2010) Malignant lymphomas consist of Hodgkin and non-hodgkin lymphomas. The current management of these diseases involves a multi-disciplinary approach.
More informationIlluminating Possibilities: Making Strides in the Treatment of B-cell Chronic Lymphocytic Leukemia (B-CLL)
Illuminating Possibilities: Making Strides in the Treatment of B-cell Chronic Lymphocytic Leukemia (B-CLL) 1 Agenda Part 1: Chronic Lymphocytic Leukemia (CLL): A Brief Review Part 2: Campath (alemtuzumab)
More informationGuidelines for the Management of Chronic Lymphocytic Leukaemia (CLL)
Guidelines for the Management of Chronic Lymphocytic Leukaemia (CLL) Version History Version Date Summary of Change/Process 2.0 08.05.08 Endorsed by the Governance Committee 2.1 16.02.11 Circulated at
More informationLymphoma and Chronic Lymphocytic Leukemia Clinical Trials
Recommendations for Implementing Assessment Criteria Guidelines in Lymphoma and Chronic Lymphocytic Leukemia Clinical Trials A PAREXEL Company Lymphoma Assessment Guidelines Standardized assessment criteria
More informationIntroduction. About 10,500 new cases of acute myelogenous leukemia are diagnosed each
Introduction 1.1 Introduction: About 10,500 new cases of acute myelogenous leukemia are diagnosed each year in the United States (Hope et al., 2003). Acute myelogenous leukemia has several names, including
More informationLeukemias and Lymphomas: A primer
Leukemias and Lymphomas: A primer Normal blood contains circulating white blood cells, red blood cells and platelets 700 red cells (oxygen) 1 white cell Neutrophils (60%) bacterial infection Lymphocytes
More informationFastTest. You ve read the book... ... now test yourself
FastTest You ve read the book...... now test yourself To ensure you have learned the key points that will improve your patient care, read the authors questions below. Please refer back to relevant sections
More informationChronic Lymphocytic Leukemia
Hematology Board Review Manual Statement of Editorial Purpose The Hospital Physician Hematology Board Review Manual is a study guide for fellows and practicing physicians preparing for board examinations
More informationHodgkin Lymphoma Disease Specific Biology and Treatment Options. John Kuruvilla
Hodgkin Lymphoma Disease Specific Biology and Treatment Options John Kuruvilla My Disclaimer This is where I work Objectives Pathobiology what makes HL different Diagnosis Staging Treatment Philosophy
More informationFrequency of NHL Subtypes in Adults
Chemotherapy Options Stephanie A. Gregory, M.D. The Elodia Kehm Professor of Medicine Director, Section of Hematology Rush University Medical Center Chicago, Illinois Frequency of NHL Subtypes in Adults
More informationDoes chronic lymphocytic leukemia increase the risk of osteoporosis?
Does chronic lymphocytic leukemia increase the risk of osteoporosis? Amrita Desai, MD Internal Medicine Residency Program Adam Olszewski, MD Department of Hematology and Oncology Memorial Hospital of Rhode
More informationchronic leukemia lymphoma myeloma differentiated 14 September 1999 Pre- Transformed Ig Surface Surface Secreted Myeloma Major malignant counterpart
Disease Usual phenotype acute leukemia precursor chronic leukemia lymphoma myeloma differentiated Pre- B-cell B-cell Transformed B-cell Plasma cell Ig Surface Surface Secreted Major malignant counterpart
More informationAdult Medical-Surgical Nursing H A E M A T O L O G Y M O D U L E : L E U K A E M I A 2
Adult Medical-Surgical Nursing H A E M A T O L O G Y M O D U L E : L E U K A E M I A 2 Leukaemia: Description A group of malignant disorders affecting: White blood cells (lymphocytes or leucocytes) Bone
More informationNovità dall EHA >> [ Leucemia linfatica cronica ]
Novità dall EHA >> [ Leucemia linfatica cronica ] Relatore: P. GHIA 27-28 ottobre 2008 Borgo S. Luigi Monteriggioni (Siena) Leucemia linfatica cronica - Copyright FSE 1 Number and type of abstracts 2 Number
More informationFDA approves Rituxan/MabThera for first-line maintenance use in follicular lymphoma
Media Release Basel, 31 January 2011 FDA approves Rituxan/MabThera for first-line maintenance use in follicular lymphoma Approval provides option that improves the length of time people with incurable
More informationA 32 year old woman comes to your clinic with neck masses for the last several weeks. Masses are discrete, non matted, firm and rubbery on
A 32 year old woman comes to your clinic with neck masses for the last several weeks. Masses are discrete, non matted, firm and rubbery on examination. She also has fever, weight loss, and sweats. What
More informationMultiple Myeloma Patient s Booklet
1E Kent Ridge Road NUHS Tower Block, Level 7 Singapore 119228 Email : ncis@nuhs.edu.sg Website : www.ncis.com.sg LIKE US ON FACEBOOK www.facebook.com/ nationaluniversitycancerinstitutesingapore Multiple
More informationGuidelines for the Management of Follicular Lymphoma
Guidelines for the Management of Follicular Lymphoma Scope The following guidance for first- and second-line therapy applies to follicular lymphoma histological grades 1, 2 and 3a according to the World
More informationLenalidomide (LEN) in Patients with Transformed Lymphoma: Results From a Large International Phase II Study (NHL-003)
Lenalidomide (LEN) in Patients with Transformed Lymphoma: Results From a Large International Phase II Study (NHL-003) Reeder CB et al. Proc ASCO 2010;Abstract 8037. Introduction > Patients (pts) with low-grade
More informationLauren Berger: Why is it so important for patients to get an accurate diagnosis of their blood cancer subtype?
Hello, I m Lauren Berger and I m the Senior Director of Patient Services Programs at The Leukemia & Lymphoma Society. I m pleased to welcome Dr. Rebecca Elstrom. Dr. Elstrom is an Assistant Professor in
More informationHistopathologic results
Self evaluation 1 Clinical Case 55-year-old woman Bilateral enlargement of cervical, axillary and inguinal lymph nodes, largest diameter > 6 cm Hepatosplenomegaly. Enlargement of retroperitoneal, mesenteric
More informationChronic lymphocytic leukemia
CHAPTER 36 Chronic lymphocytic leukemia Jorge E. Cortes, MD, Susan O Brien, MD, and Mark A. Weiss, MD Chronic lymphocytic leukemia (CLL) is a clonal malignancy that results from expansion of the mature
More informationSOUTHWEST ONCOLOGY GROUP CLINICAL RESEARCH ASSOCIATE (CRA) MANUAL. MYELOMA CHAPTER 10 REVISED: March 2008
Introduction This disease site includes the following three malignancies: multiple myeloma, amyloidosis, and waldenstrom's macroglobulinemia. See pages 4 and 5 for descriptions of the latter two diseases.
More informationPROGNOSIS IN ACUTE LYMPHOBLASTIC LEUKEMIA PROGNOSIS IN ACUTE MYELOID LEUKEMIA
PROGNOSIS IN ACUTE LYMPHOBLASTIC LEUKEMIA UNFAVORABLE Advanced age High leukocyte count at diagnosis Presence of myeloid antigens Late achievement of CR Chromosomal abnormalities: t(9:22)(q34:q11) t(4;11)(q21;q23)
More informationACUTE MYELOID LEUKEMIA (AML),
1 ACUTE MYELOID LEUKEMIA (AML), ALSO KNOWN AS ACUTE MYELOGENOUS LEUKEMIA WHAT IS CANCER? The body is made up of hundreds of millions of living cells. Normal body cells grow, divide, and die in an orderly
More informationInteresting Case Series. Periorbital Richter Syndrome
Interesting Case Series Periorbital Richter Syndrome MarkGorman,MRCS,MSc, a Julia Ruston, MRCS, b and Sarath Vennam, BMBS a a Division of Plastic Surgery, Royal Devon and Exeter Hospital, Exeter, Devon,
More informationGuidelines on the diagnosis and management of chronic lymphocytic leukaemia
guideline Guidelines on the diagnosis and management of chronic lymphocytic leukaemia Methods The purpose of this guideline is to provide a rational approach to the diagnosis and management of patients
More informationMULTIPLE MYELOMA. Dr Malkit S Riyat. MBChB, FRCPath(UK) Consultant Haematologist
MULTIPLE MYELOMA Dr Malkit S Riyat MBChB, FRCPath(UK) Consultant Haematologist Multiple myeloma is an incurable malignancy that arises from postgerminal centre, somatically hypermutated B cells.
More informationSWOG ONCOLOGY RESEARCH PROFESSIONAL (ORP) MANUAL VOLUME I RESPONSE ASSESSMENT LEUKEMIA CHAPTER 11A REVISED: OCTOBER 2015
LEUKEMIA Response in Acute Myeloid Leukemia (AML) Response criteria in Acute Myeloid Leukemia for SWOG protocols is based on the review article Diagnosis and management of acute myeloid leukemia in adults:
More informationHOVON Staging and Response Criteria for Non-Hodgkin s Lymphomas Page 1
HOVON Staging and Response Criteria for Non-Hodgkin s Lymphomas Page 1 This document describes the minimally required staging and evaluation procedures and response criteria that will be applied in all
More informationLymphoma Diagnosis and Classification
Lymphoma Diagnosis and Classification By Atef Shrit, MD, Pathology B- and T/NK-cell lymphomas are clonal neoplasms of immature and mature B-lymphocytes, T-lymphocytes or natural killer cells at various
More informationLYMPHOMA IN DOGS. Diagnosis/Initial evaluation. Treatment and Prognosis
LYMPHOMA IN DOGS Lymphoma is a relatively common cancer in dogs. It is a cancer of lymphocytes (a type of white blood cell) and lymphoid tissues. Lymphoid tissue is normally present in many places in the
More informationCHAPTER 26 LATE BREAKING DEVELOPMENTS: IMPACT OF ANTI-CD20 MONOCLONAL ANTIBODIES ON LYMPHOMA THERAPY
CHAPTER 26 LATE BREAKING DEVELOPMENTS: IMPACT OF ANTI-CD20 MONOCLONAL ANTIBODIES ON LYMPHOMA THERAPY 26.1 Introduction rituximab Subsequent to the completion of drafts for the guidelines earlier in 2004,
More informationHairy Cell Leukemia Facts
No. 16 in a series providing the latest information for patients, caregivers and healthcare professionals www.lls.org Information Specialist: 800.955.4572 Highlights l Hairy cell leukemia (HCL) is a chronic
More informationEstimated New Cases of Leukemia, Lymphoma, Myeloma 2014
ABOUT BLOOD CANCERS Leukemia, Hodgkin lymphoma (HL), non-hodgkin lymphoma (NHL), myeloma, myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPNs) are types of cancer that can affect the
More informationPROTOCOLS FOR TREATMENT OF MALIGNANT LYMPHOMA
2012 1 31,, PROTOCOLS FOR TREATMENT OF MALIGNANT LYMPHOMA Version 1.0 2012 DIVISION OF HAEMATOLOGY / ONCOLOGY DEPARTMENT OF MEDICINE KAOHSING VETERAN GENERAL HOSPTIAL General Guide Diagnosis 1.Adequate
More informationEmerging New Prognostic Scoring Systems in Myelodysplastic Syndromes 2012
Emerging New Prognostic Scoring Systems in Myelodysplastic Syndromes 2012 Arjan A. van de Loosdrecht, MD, PhD Department of Hematology VU University Medical Center VU-Institute of Cancer and Immunology
More informationHematopathology VII Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, And Hairy Cell Leukemia
John L. Kennedy, M.D. UIC College of Medicine Associate Professor of Clinical Pathology M2 Pathology Course Lead Pathologist, VA Chicago Health Care System Lecture #43 Phone: (312) 569-6690 Thursday, November
More informationEVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT
perc also deliberated on the alignment of bendamustine with patient values. perc noted that bendamustine has a progression-free survival advantage, may be less toxic than currently available therapies
More informationShaji Kumar, M.D. Multiple Myeloma: Multiple myeloma (MM) is the second most common hematological
An update on the management of multiple myeloma and amyloidosis Shaji Kumar, M.D. Multiple Myeloma: Multiple myeloma (MM) is the second most common hematological malignancy in this country affecting nearly
More informationUpdate in Hematology Oncology Targeted Therapies. Mark Holguin
Update in Hematology Oncology Targeted Therapies Mark Holguin 25 years ago Why I chose oncology People How to help people with possibly the most difficult thing they may have to deal with Science Turning
More informationfor Leucocyte Immunophenotyping Leukaemia Diagnosis Interpretation All Participants Date Issued: 08-September-2014 Closing Date: 26-September-2014
for Leucocyte Immunophenotyping Leukaemia Interpretation All Participants Participant: 4xxxx Trial No: 141502 Date Issued: 08-September-2014 Closing Date: 26-September-2014 Trial Comments This was an electronic
More informationOPTIMIZING TREATMENT OF CHRONIC LEUKEMIA: CHRONIC LYMPHOCYTIC LEUKEMIA AND CHRONIC MYELOID LEUKEMIA
Volume 9 Number 12S December 2012 OPTIMIZING TREATMENT OF CHRONIC LEUKEMIA: CHRONIC LYMPHOCYTIC LEUKEMIA AND CHRONIC MYELOID LEUKEMIA S77 Managing the patient with chronic lymphocytic leukemia: initial
More informationThings You Don t Want to Miss in Multiple Myeloma
Things You Don t Want to Miss in Multiple Myeloma Sreenivasa Chandana, MD, PhD Attending Hematologist and Medical Oncologist West Michigan Cancer Center Assistant Professor, Western Michigan University
More informationBone Marrow Evaluation for Lymphoma. Faizi Ali, MD Hematopathology Fellow William Beaumont Hospital
Bone Marrow Evaluation for Lymphoma Faizi Ali, MD Hematopathology Fellow William Beaumont Hospital Indications One of the most common indications for a bone marrow biopsy is to evaluate for malignant lymphoma.
More informationChronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia June, CLL survivor This publication was supported by Revised 2014 A Message from Louis J. DeGennaro, PhD President and CEO of The Leukemia & Lymphoma Society The Leukemia &
More informationFlow Cytometric Diagnosis of Low Grade B-cell Leukemia/Lymphoma
Flow Cytometric Diagnosis of Low Grade B-cell Leukemia/Lymphoma Maryalice Stetler-Stevenson, M.D., Ph.D. Flow Cytometry Unit, Laboratory of Pathology, DCS, NCI,NIH DEPARTMENT OF HEALTH & HUMAN SERVICES
More informationNew Targets and Treatments for Follicular Lymphoma. Disclosures
Winship Cancer Institute of Emory University New Targets and Treatments for Follicular Lymphoma Jonathon B. Cohen, MD, MS Assistant Professor Div of BMT, Emory University Disclosures Consulting fees from:
More informationCharacteristics and Prognosis of Patients with Richter s Transformation of Chronic Lymphocytic Leukemia: Experience with FDG/PET
Characteristics and Prognosis of Patients with Richter s Transformation of Chronic Lymphocytic Leukemia: Experience with FDG/PET Lorenzo Falchi, Long Trinh, Edith M Marom, Mylene Truong, Ellen J Schlette,
More informationEU Media Inquiries: Satu Kaarina Glawe Phone: +49 (0) 2638 947 9218 Mobile: +49 (172) 294 6264 Email: sglawe@its.jnj.com
EU Media Inquiries: Satu Kaarina Glawe Phone: +49 (0) 2638 947 9218 Mobile: +49 (172) 294 6264 Email: sglawe@its.jnj.com Investor Relations: Stan Panasewicz Phone: +1 732-524-2524 Louise Mehrotra Phone:
More informationThe Blood Cancer Twice As Likely To Affect African Americans: Multiple Myeloma
The Blood Cancer Twice As Likely To Affect African Americans: Multiple Myeloma 11 th Annual National Leadership Summit on Health Disparities Innovation Towards Reducing Disparities Congressional Black
More informationCutaneous Lymphoma FAST FACTS
Cutaneous Lymphoma FAST FACTS What is Cutaneous Lymphoma? Cutaneous lymphomas are types of non-hodgkin s lymphomas (NHL) that originate in the lymphocytes (white blood cells). Unlike most other types of
More informationRole of taxanes in the treatment of advanced NHL patients: A randomized study of 87 cases
Role of taxanes in the treatment of advanced NHL patients: A randomized study of 87 cases R. Shraddha, P.N. Pandit Radium Institute, Patna Medical College and Hospital, Patna, India Abstract NHL is a highly
More informationChromosome 6 Abnormalities Associated with Prolymphocytic Acceleration in Chronic Lymphocytic Leukemia* f
ANNALS OF CLINICAL AND LABORATORY SCIENCE, Vol. 28, No. 1 Copyright 1998, Institute for Clinical Science, Inc. Chromosome 6 Abnormalities Associated with Prolymphocytic Acceleration in Chronic Lymphocytic
More informationChronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia Session Chair: Neil E. Kay, MD Speakers: Neil E. Kay, MD; Vicki A. Morrison, MD; and Lynn R. Goldin, PhD Comprehensive Management of the CLL Patient: A Holistic Approach Tait
More informationSMALL CELL LUNG CANCER
Protocol for Planning and Treatment The process to be followed in the management of: SMALL CELL LUNG CANCER Patient information given at each stage following agreed information pathway 1. DIAGNOSIS New
More informationWith more than 15 000 cases recognized annually, Chronic Lymphocytic Leukemia A Clinical Review. Clinical Review & Education.
Clinical Review & Education Review A Clinical Review Chadi Nabhan, MD; Steven T. Rosen, MD IMPORTANCE The most common leukemia is chronic lymphocytic leukemia (CLL). Every year, there are 15 000 new diagnoses
More informationResponse Criteria for Malignant Lymphoma 2007. Cheson Criteria. Quick Reference Guide
Response Criteria for Malignant Lymphoma 2007 Cheson Criteria Quick Reference Guide Table of Contents Summary of Assessments...3 Baseline Lesion Burden...4 What isameasurable Lesion?...5 Choosing Target
More informationMULTIPLE MYELOMA 1 PLASMA CELL DISORDERS Multiple l Myeloma Monoclonal Gammopathy of Undetermined Significance (MGUS) Smoldering Multiple Myeloma (SMM) Solitary Plasmacytoma Waldenstrom s Macroglobulinemia
More informationMantle Cell Lymphoma Understanding Your Treatment Options
New Developments in Mantle Cell Lymphoma John P. Leonard, M.D. Richard T. Silver Distinguished Professor of Hematology and Medical Oncology Associate Dean for Clinical Research Vice Chairman, Department
More informationLEUKEMIA LYMPHOMA MYELOMA Advances in Clinical Trials
LEUKEMIA LYMPHOMA MYELOMA Advances in Clinical Trials OUR FOCUS ABOUT emerging treatments Presentation for: Judith E. Karp, MD Advancements for Acute Myelogenous Leukemia Supported by an unrestricted educational
More informationU.S. Food and Drug Administration
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA s website for reference purposes only. It was current when produced, but is no longer maintained
More informationAnalysis of Prostate Cancer at Easter Connecticut Health Network Using Cancer Registry Data
The 2014 Cancer Program Annual Public Reporting of Outcomes/Annual Site Analysis Statistical Data from 2013 More than 70 percent of all newly diagnosed cancer patients are treated in the more than 1,500
More informationTreatment of low-grade non-hodgkin lymphoma
Produced 28.02.2011 Due for revision 28.02.2013 Treatment of low-grade non-hodgkin lymphoma Lymphomas are described as low grade if the cells appear to be dividing slowly. There are several kinds of low-grade
More informationAnti-HCV therapy in HCV-related NHL
Gabriele Pozzato M.D. University of Trieste Anti-HCV therapy in HCV-related NHL Questions about HCV+ in NHL Is the NHL related with HCV infection? Which is the best therapeutic strategy? Is the antiviral
More informationFLUDARABINE AS FIRST LINE THERAPY FOR CHRONIC LYMPHOCYTIC LEUKAEMIA
FLUDARABINE AS FIRST LINE THERAPY FOR CHRONIC LYMPHOCYTIC LEUKAEMIA A West Midlands Health Technology Assessment Collaboration report Authors: Sarah Hancock, Research Reviewer and Analyst Beverley Wake,
More informationNon-Hodgkin Lymphoma Richard Orlowski, MD
Non-Hodgkin Lymphoma Richard Orlowski, MD The American Cancer Society (ACS) estimates that 69,740 Americans will be diagnosed with non-hodgkin lymphoma (NHL) in 2013. Excluding non-melanoma skin cancers,
More informationLong Term Low Dose Maintenance Chemotherapy in the Treatment of Acute Myeloid Leukemia
Long Term Low Dose Chemotherapy in the Treatment of Acute Myeloid Leukemia Murat TOMBULO LU*, Seçkin ÇA IRGAN* * Department of Hematology, Faculty of Medicine, Ege University, zmir, TURKEY ABSTRACT In
More informationCML. cure. A Patient s Guide. Molecular Biology Diagnosis Stem Cell Transplant Monitoring New Drugs Questions to Ask and More
A Patient s Guide to CML Molecular Biology Diagnosis Stem Cell Transplant Monitoring New Drugs Questions to Ask and More cure C a n c e r U p d at e s, R e s e a r c h & E d u c at i o n Based on science,
More informationMULTIPLE MYELOMA Review & Update for Primary Care. Dr. Joseph Mignone 21st Century Oncology
MULTIPLE MYELOMA Review & Update for Primary Care Dr. Joseph Mignone 21st Century Oncology OVERVIEW Identify the diagnostic criteria for multiple myeloma Compare first & second line therapies, using data
More informationCLL. Handheld record. Stockport NHS foundation trust
CLL 2015 Handheld record Contains- Patient information booklet, details of haematology clinic assessment and ongoing clinical assessment at GP surgery Stockport NHS foundation trust You have been diagnosed
More informationWho is affected by HCL and what causes it?
Freephone helpline 0808 808 5555 information@lymphomas.org.uk www.lymphomas.org.uk Hairy cell leukaemia Hairy cell leukaemia (HCL) is a rare and very distinctive cancer of blood cells called B lymphocytes
More informationWhat is non-hodgkin lymphoma, how is it treated, and what is the unmet need?
What is non-hodgkin lymphoma, how is it treated, and what is the unmet need? Tim Illidge BSc PhD MRCP FRCR FRCPath Institute of Cancer Sciences, University of Manchester Manchester Cancer Research Centre,
More informationUpdate on Follicular Lymphoma. Brad Kahl, M.D.
Update on Follicular Lymphoma Brad Kahl, M.D. Follicular Lymphoma: 25% of NHL Cases Other subtypes (9%) T and NK cell (12%) Burkitt (2.5%) Diffuse large B cell (DLBCL) (30%) Mantle cell (6%) Follicular
More informationBendamustine with rituximab for the first-line treatment of advanced indolent non-hodgkin's and mantle cell lymphoma
LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Bendamustine with rituximab for the first-line treatment of advanced indolent non-hodgkin's and mantle cell lymphoma Bendamustine with rituximab for the first-line
More informationProtein kinase C alpha expression and resistance to neo-adjuvant gemcitabine-containing chemotherapy in non-small cell lung cancer
Protein kinase C alpha expression and resistance to neo-adjuvant gemcitabine-containing chemotherapy in non-small cell lung cancer Dan Vogl Lay Abstract Early stage non-small cell lung cancer can be cured
More informationBendamustine for the fourth-line treatment of multiple myeloma
LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Bendamustine for the fourth-line treatment of multiple myeloma Contents Summary 1 Background 2 Epidemiology 3 Cost 6 References 7 Summary There is no standard
More informationCurrent Multiple Myeloma Treatment Adapted From the NCCN Guidelines
Current Multiple Myeloma Treatment Adapted From the NCCN Guidelines Diagnosis Survival 3-5 yrs Survival
More informationMany people with non-hodgkin lymphoma have found an educational support group helpful. Support
Track 2: Treatment Options [Narrator] Many people with non-hodgkin lymphoma have found an educational support group helpful. Support groups take many forms: some meet the needs of people with all kinds
More informationAre CAR T-Cells the Solution for Chemotherapy Refractory Diffuse Large B-Cell Lymphoma? Umar Farooq, MD University of Iowa Hospitals and Clinics
Are CAR T-Cells the Solution for Chemotherapy Refractory Diffuse Large B-Cell Lymphoma? Umar Farooq, MD University of Iowa Hospitals and Clinics Disclosure(s) I do not intend to discuss an off-label use
More informationIF AT FIRST YOU DON T SUCCEED: TRIAL, TRIAL AGAIN
+ IF AT FIRST YOU DON T SUCCEED: TRIAL, TRIAL AGAIN Rena Buckstein MD FRCPC Head Hematology Site Group Sunnybrook Odette Cancer Center (OCC) Head of Hematology Clinical Trials Group at OCC + Outline Start
More informationCollaboration to collect Autologous transplant outcomes in Lymphoma and Myeloma (CALM) Additional Questionnaire (MED C) INCLUSION CRITERIA CALM STUDY
Additional Questionnaire (MED C) CALM study Inclusion period: 01/01/2008 to 31/12/2011 PATIENT REGISTRATION FORM Disease Diagnosis Lymphoma S Non Hodgkin Lymphoma (NHL) Mature B-cell neoplasm Follicular
More informationStem Cell Transplantation
Harmony Behavioral Health, Inc. Harmony Behavioral Health of Florida, Inc. Harmony Health Plan of Illinois, Inc. HealthEase of Florida, Inc. Ohana Health Plan, a plan offered by WellCare Health Insurance
More information